Display options
Cite
Dalgleish AG, Perry MJ, Eaton JD, et al. The immunotherapy of prostate cancer. Prostate Cancer Prostatic Dis. 2000;3(4):303-307doi: 10.1038/sj.pcan.4500487.
Dalgleish, A. G., Perry, M. J., Eaton, J. D., Hrouda, D., Todryk, S. M., & Kirby, R. S. (2000). The immunotherapy of prostate cancer. Prostate cancer and prostatic diseases, 3(4), 303-307. https://doi.org/10.1038/sj.pcan.4500487
Dalgleish, A G, et al. "The immunotherapy of prostate cancer." Prostate cancer and prostatic diseases vol. 3,4 (2000): 303-307. doi: https://doi.org/10.1038/sj.pcan.4500487
Dalgleish AG, Perry MJ, Eaton JD, Hrouda D, Todryk SM, Kirby RS. The immunotherapy of prostate cancer. Prostate Cancer Prostatic Dis. 2000 Dec;3(4):303-307. doi: 10.1038/sj.pcan.4500487. PMID: 12497083.
Copy Download .nbib Format: NLM
Share it on

Prostate Cancer Prostatic Dis. 2000 Dec;3(4):303-307. doi: 10.1038/sj.pcan.4500487.

The immunotherapy of prostate cancer.

Prostate cancer and prostatic diseases

A G Dalgleish, M J A Perry, J D Eaton, D Hrouda, S M Todryk, R S Kirby

Affiliations

  1. Deparments of Oncology/Urology, St George's Hospital and Medical School, London, UK.

PMID: 12497083 DOI: 10.1038/sj.pcan.4500487

Abstract

Advanced prostate cancer remains incurable with standard treatment options. Immunotherapy may be a realistic alternative given the growing evidence that the immune response can affect the growth of other solid tumours and the regulation of both specific and shared prostate cancer antigens. Early studies suggest that both non-specific and specific vaccines can effect relevant animal models and clinical trials based on these observations are now in progress. A number of other approaches including gene therapy with HSVtk are already undergoing clinical studies (Herman et al. Hum Gene Ther 1999; 10: 1239-1249). Prostate Cancer and Prostatic Diseases (2000) 3, 303-307

Publication Types